Skip to main content
Huaren Pharmaceutical Co.,Ltd. logo

Huaren Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 300110 ISIN · CNE100000SW1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,015 across all filing types
Latest filing 2026-05-25 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300110

About Huaren Pharmaceutical Co.,Ltd.

https://www.qdhuaren.com

Huaren Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of high-quality pharmaceutical products and medical supplies. The company is a leading provider of large-volume parenteral (LVP) solutions, particularly non-PVC soft bag intravenous infusions, which are utilized across various clinical settings. Its product portfolio encompasses basic infusions, therapeutic infusions, and specialized solutions such as peritoneal dialysis fluids for the treatment of end-stage renal disease. In addition to its core pharmaceutical offerings, the company produces medical consumables, pharmaceutical packaging materials, and health-related products. Huaren Pharmaceutical emphasizes technological innovation and quality control in its production processes to ensure patient safety and clinical efficacy. The company serves a broad network of healthcare institutions, focusing on delivering integrated solutions for fluid therapy and specialized medical care.

Recent filings

Filing Released Lang Actions
关于为子公司提供担保的进展公告
Capital/Financing Update Classification · 90% confidence The document is a corporate announcement detailing the progress of guarantees provided by the parent company for its subsidiary’s financing facilities. It is not a full financial report, AGM material, earnings release, or a regulatory certification, but rather a financing activity update describing the guarantee amounts, counterparties, and terms. This fits the definition of a Capital/Financing Update (CAP).
2026-05-25 Chinese
北京植德（青岛）律师事务所关于华仁药业股份有限公司2025年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 77% confidence The document is a legal opinion (“法律意见书”) prepared by an external law firm regarding the company’s 2025 annual general shareholders’ meeting. It details the convening procedures, attendance qualifications, voting procedures, and, crucially, publishes the full voting results for each proposal. This aligns with the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-15 Chinese
第八届董事会第十四次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is an official announcement of the board of directors’ resolutions at a temporary board meeting, detailing the dismissal and appointment of senior management (vice president and CFO). This falls under announcements of changes in the company’s board or senior management. Therefore, it is classified as Board/Management Information (MANG).
2026-05-15 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 91% confidence The document is a formal announcement of the resolutions and voting results from the company’s 2025 Annual Shareholders’ Meeting (AGM), detailing the attendance, vote counts on each proposal, and confirmations by legal counsel. This exactly matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-15 Chinese
关于公司高级管理人员变动的公告
Board/Management Information Classification · 90% confidence The document is an official announcement titled “关于公司高级管理人员变动的公告” (Announcement on Changes in Senior Management). It details the non-reappointment of the current CFO and the appointment of a new Vice President/CFO, including board resolutions, committee approvals, and biographical details. This clearly fits the definition of a Board/Management Information filing, as it announces changes in senior management.
2026-05-15 Chinese
2025年度独立董事述职报告（范英杰）
Governance Information Classification · 82% confidence The document is titled “2025年度独立董事述职报告” (Independent Director’s Annual Performance Report) by范英杰, detailing attendance at board and committee meetings, communication with auditors, protection of investor rights, and governance-related duties. It is not a financial statement (10-K, IR), not an earnings release, not a proxy or dividend notice, nor a management change announcement. Instead, it is a corporate governance disclosure focused on board processes, independent director duties, and governance practices. Thus it falls under Governance Information (CGR).
2026-04-23 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.